LONDON, UK: The Royal Marsden NHS Foundation Trust, a world-leading specialist cancer center, has today announced a pioneering partnership with NTT DATA, a global leader in digital business and technology services, and CARPL.ai, a leading enterprise imaging artificial intelligence (AI) and machine learning operations (MLOps) platform. Together, they have designed and built an advanced AI-powered radiology analysis service for the development and evaluation of AI in medical imaging, designed to transform cancer research and, ultimately, improve patient outcomes.

AI’s potential to enhance the speed and accuracy of identifying imaging biomarkers has long been recognized. Funded by a three-year grant from the UK’s National Institute for Health and Care Research (NIHR), the service will be used for research at The Royal Marsden and the Institute of Cancer Research (ICR), including projects in collaboration with other research teams. This research initiative will focus on developing and evaluating AI algorithms to improve the accuracy of cancer evaluation, including sarcoma, lung, breast, brain, and prostate cancers. This will lead to faster response times, more accurate diagnoses, and better-targeted treatments.

The service runs on an MLOps clinical imaging platform, built and operated by NTT DATA. To enable this, NTT DATA developed a bespoke AI computing solution leveraging high-performance Dell servers and utilizing the latest GPU processing capacity orchestrated by the CARPL.ai platform, which helps test and manage AI algorithms and includes a large collection of radiology AI models.

NTT DATA is also providing specialist imaging AI consulting services, helping researchers at The Royal Marsden test and evaluate emerging AI tools in real clinical settings, while extracting maximum insight and value from both in-house and commercial algorithms.

“AI has immense potential to support clinicians in diagnosing and treating cancer earlier and more precisely,” said Professor Dow-Mu Koh, Professor in Functional Cancer Imaging and Consultant Radiologist in Functional Imaging at The Royal Marsden. “By working with NTT DATA and CARPL.ai, we’ve created a scalable research environment that allows us to explore the full potential of AI safely and in a way that could one day transform cancer diagnosis and treatment across the NHS.”

Minister of State for Health, Karin Smyth, said: “Our 10-Year Health Plan will modernize the NHS, replacing outdated systems with cutting-edge digital solutions. While this trial is in its early stages, it represents exactly the kind of collaboration between the NHS, industry, and academia that will help build a health service fit for the future. Early detection saves lives, and innovations like AI will transform how cancer is diagnosed and treated – helping patients receive faster and more effective care.”

Professor Mike Lewis, NIHR Scientific Director for Innovation, said: “Cancer is one of the biggest killers in the UK. That must change. This three-year grant will help researchers push the boundaries of AI-driven technology for cancer detection and diagnosis.

This AI-powered service represents the cutting edge of cancer research, and it is going to transform treatment, better support NHS staff, and ultimately change patients’ lives. It is another great example of how NIHR-funded and supported research will ensure the best care is there when patients need it.”

Tom Winstanley, Chief Technology Officer at NTT DATA UK & Ireland, commented: “This service is a great example of responsible innovation in practice, showing the ethical, secure use of AI in healthcare. We are very proud to support The Royal Marsden in pushing the boundaries of cancer research.”

Once the service is live, research teams at The Royal Marsden will be able to evaluate a range of AI models across several cancer types. These studies will generate critical insights into how AI can support clinical decision-making and shape future approaches to diagnosis and treatment. Through CARPL.ai’s centralized interface and built-in monitoring tools, the research teams will also be able to track model performance over time, enabling faster feedback loops between development and deployment – a crucial step towards clinical translation. NTT DATA will continue to work closely with The Royal Marsden to support this next phase of research, which will ultimately improve cancer care and patient outcomes.

The post The Royal Marsden NHS Foundation Trust Collaborates with NTT DATA and CARPL.ai appeared first on NRI News.

Unveiled its enhanced portfolio the Non-DICOM printer – APEOS along with its service & support mobile application “FUJIFILM Connect”

Showcased a wide range of healthcare Imaging solutions devices to support the radiology fraternity

INDIA: FUJIFILM India, a pioneer in healthcare imaging and information systems, announced the expansion of its product and solutions portfolio at the 75th National Conference of the Indian Radiological and Imaging Association (IRIA). During the four-day long conference, scheduled from 2nd – 5th February 2023 at Amritsar, FUJIFILM India unveiled revolutionary diagnostic machines. The new range includes the ultrasound system Arietta 850 DeepInsight and Arietta 650 DeepInsight along with the new MRI machine APERTO Lucent Non-DICOM printer APEOS. Additionally, the company also introduced the “FUJIFILM Connect” service & support mobile applications.

The APERTO Lucent is a new-age, Prime open MRI device which is equipped with IP-RAPID – a modern-day technique that reduces scan times while maintaining high image quality by employing under-sampling and image reconstruction with iterative processing which will result in Improved image quality with higher spatial resolution. The design of APERTO Lucent will provide high-speed solutions combined with a better patient experience.

Launched at IRIA 2023, the Arietta 850 DeepInsight and Arietta 650 DeepInsight are the latest ultrasound technology offering from FUJIFILM India. The new imaging brand “DeepInsight” consists of 5 elements Accuracy, Reproducibility, Visibility, Efficiency & Utilization of AI. The Utilization of AI means achieving an enhanced level of diagnostic image quality by the new technology which utilizes AI and it is “DeepInsight Technology”. We believe that the new imaging brand “DeepInsight” can overcome the challenges our customers face, such as noisy images, examiner and patient dependencies, etc. “DeepInsight” can let clnincian achieve a more confident diagnoses by delivering these 5 essential elements. The combination of the “DeepInsight Technology” as well as our existing core technology of “refocusing” and “Carving Imaging” allows us to produce the ideal ultrasound image.

The FDX Visionary-DR launched at IRIA 2023 is a bone density scanner that will support for a wide range of solutions for Bone Densitometry and Body Composition Analysis. The product is an advanced system using 2D-Fan Beam technology to perform fast and high image quality examinations. It offers good Connectivity features where multiple users on different workstations can quickly import or export exams through DICOM from FDX Visionary-DR to the PACS and RIS. It is positioned to provide a comfortable diagnostic experience for both patients and practitioners.

Also introduced at the exhibition was the APEOS medical printer which is a compact multifunction and single-function A4 Laser Printer. This easy-to-manage & control printer is Powerful and Multi-feature oriented, combined with a high-yield toner cartridge & a fast-printing capacity. Available with numerous versatile features, this is compatible with ultrasound and endoscopy, non-DICOM images.

The Fujifilm Healthcare, Service & Support Mobile App “FUJIFILM Connect” was also launched at this event by dignitaries & committee members of IRIA. The mobile app is a one-stop solution to manage the service and support of Fujifilm Healthcare products. Made with the latest User Interface standards, the mobile app will have sections of “My Products” that will store details of the products used, “Raise tickets” to register a complaint from the app along with “Explore Products” where customers can explore the range of FUJIFILM healthcare products and enquire to buy them as well. The effort is to enhance the convenience and the user experience of customers.

As part of the event, FUJIFILM India also displayed its latest healthcare medical devices like Full Field Digital Mammography (FFDM) – Amulet Innovality, Healthcare IT: Synapse PACS, USG – Arietta and FDR: X-air. The cutting-edge Amulet Innovality is a highly advanced breast cancer diagnostic tool that enables women to experience early detection of breast cancer. The SYNAPSE PACS improves efficiency and workflow whilst enhancing access to patient data. The Arietta Series of Ultrasound is designed to provide high-quality imaging across a broad clinical range that includes abdominal, cardiac, and vascular applications ensuring enhanced accuracy and safety to transform ultrasound diagnosis. Ultralight, compact, battery-powered, and portable digital X-ray machine, FDR Xair helps combine deep learning in its artificial intelligence (AI) technology with Fujifilm’s image processing heritage.

Milind Soman, Brand Ambassador for Healthcare and Instax Division, FUJIFILM India said, “Health should always be a primary concern for everyone. A healthy physique is significant for quality living and the best defense against numerous diseases in the world. I extend my strong support to FUJIFILM India for contributing towards a healthy future for people and providing them with quality healthcare, which is a powerful weapon for the early detection of curable diseases. It is an honor to be associated with a leading imaging brand to support them in this cause which envisions raising awareness around the early screening of diseases and making the world a healthy place.”

Speaking on the occasion Mr. Chander Shekhar Sibal, Executive Vice President & Head of the Medical Division at FUJIFILM India said, “Today’s healthcare enterprises are entirely focused on improving the quality of healthcare and FUJIFILM India has always been at the forefront of healthcare innovation and advanced imaging solutions keeping in mind the industry needs. With the new launches at IRIA, our aim is to provide high-value healthcare imaging solutions using cutting-edge technologies as digitalization and AI in healthcare become more prevalent. We are honored to present our diverse range of medical systems at this year’s IRIA. We created these technologies to provide patients with comfortable and efficient procedures while also assisting clinicians in providing the best possible patient outcomes.”

FUJIFILM India has consistently pushed forward to improve healthcare diagnostic standards, helping to make the world better and fitter. As a result, FUJIFILM India is continually using technology to produce forward-thinking medical equipment and technologies in order to construct a line of medical care that will strengthen the country’s medical infrastructure and provide healthcare facilities to millions of people. FUJIFILM is committed to providing Indians with the most cost-effective diagnostic technologies available. Its technical and innovative prowess is unrivaled in the business, and with each passing year, it cements its position as the industry’s pioneer in medical imaging and other diagnostic services.

The post FUJIFILM India unveils its new range of Healthcare imaging products at IRIA 2023 appeared first on NRI News.